PD-1 Non-Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major PD-1 non-small cell lung cancer markets are expected to exhibit a CAGR of 6.54% during 2024-2034.
The PD-1 non-small cell lung cancer market has been comprehensively analyzed in IMARC's new report titled "PD-1 Non-Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". PD-1 non-small cell lung cancer refers to a specific type of oncological disease in which cancerous cells express the programmed death-ligand 1 (PD-L1) on their surface. In this condition, PD-L1 binds to PD-1 receptors on T cells and inhibits their activity, thereby suppressing the immune response against the tumors. The interaction allows cancerous cells to evade the body's defense processes and continue to grow and spread. Individuals suffering from the illness may experience persistent coughing, shortness of breath, fatigue, chest and bone pain, unintended weight loss, hoarseness or a change in voice, lack of appetite, difficulty swallowing, headaches, seizures, dizziness, etc. The diagnosis of this ailment is mainly based on the patient's characteristic features, medical history review, and physical examination. Additionally, molecular testing may be performed on the tumor tissue sample to aid in identifying specific genetic changes or mutations in the cancerous cells, including those related to PD-1 expression. Numerous imaging studies, such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, etc., are commonly used to detect lung cancer and determine its stage.
The rising prevalence of genetic mutations and the escalating demand for therapies that can address gene defects associated with the disease are primarily driving the PD-1 non-small cell lung cancer market. Furthermore, the increasing utilization of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for treating oncological conditions that have become resistant to conventional therapeutic techniques is acting as another significant growth-inducing factor. Apart from this, the widespread adoption of platinum-based chemotherapy coupled with anti-PD-1 antibodies, which allow a more robust and targeted response against cancerous cells by amplifying the immune reactions in patients, is further creating a positive outlook for the market. Moreover, numerous regulatory authorities are implementing favorable policies, like limiting the approval process to encourage the research and commercialization of anti-PD-1 therapy for lung cancer. This, in turn, is also augmenting the market growth. Additionally, the emerging popularity of next-generation sequencing techniques, a minimally invasive method for monitoring condition worsening, treatment response, and minimal residual disease after anti-PD-1 therapy, is expected to drive the PD-1 non-small cell lung cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the PD-1 non-small cell lung cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for PD-1 non-small cell lung cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the PD-1 non-small cell lung cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the PD-1 non-small cell lung cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the PD-1 non-small cell lung cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current PD-1 non-small cell lung cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the PD-1 non-small cell lung cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the PD-1 non-small cell lung cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the PD-1 non-small cell lung cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with PD-1 non-small cell lung cancer across the seven major markets?
What is the size of the PD-1 non-small cell lung cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of PD-1 non-small cell lung cancer?
What will be the growth rate of patients across the seven major markets?
PD-1 Non-Small Cell Lung Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for PD-1 non-small cell lung cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the PD-1 non-small cell lung cancer market?
What are the key regulatory events related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by status related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by phase related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by route of administration related to the PD-1 non-small cell lung cancer market?
The PD-1 non-small cell lung cancer market has been comprehensively analyzed in IMARC's new report titled "PD-1 Non-Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". PD-1 non-small cell lung cancer refers to a specific type of oncological disease in which cancerous cells express the programmed death-ligand 1 (PD-L1) on their surface. In this condition, PD-L1 binds to PD-1 receptors on T cells and inhibits their activity, thereby suppressing the immune response against the tumors. The interaction allows cancerous cells to evade the body's defense processes and continue to grow and spread. Individuals suffering from the illness may experience persistent coughing, shortness of breath, fatigue, chest and bone pain, unintended weight loss, hoarseness or a change in voice, lack of appetite, difficulty swallowing, headaches, seizures, dizziness, etc. The diagnosis of this ailment is mainly based on the patient's characteristic features, medical history review, and physical examination. Additionally, molecular testing may be performed on the tumor tissue sample to aid in identifying specific genetic changes or mutations in the cancerous cells, including those related to PD-1 expression. Numerous imaging studies, such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, etc., are commonly used to detect lung cancer and determine its stage.
The rising prevalence of genetic mutations and the escalating demand for therapies that can address gene defects associated with the disease are primarily driving the PD-1 non-small cell lung cancer market. Furthermore, the increasing utilization of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for treating oncological conditions that have become resistant to conventional therapeutic techniques is acting as another significant growth-inducing factor. Apart from this, the widespread adoption of platinum-based chemotherapy coupled with anti-PD-1 antibodies, which allow a more robust and targeted response against cancerous cells by amplifying the immune reactions in patients, is further creating a positive outlook for the market. Moreover, numerous regulatory authorities are implementing favorable policies, like limiting the approval process to encourage the research and commercialization of anti-PD-1 therapy for lung cancer. This, in turn, is also augmenting the market growth. Additionally, the emerging popularity of next-generation sequencing techniques, a minimally invasive method for monitoring condition worsening, treatment response, and minimal residual disease after anti-PD-1 therapy, is expected to drive the PD-1 non-small cell lung cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the PD-1 non-small cell lung cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for PD-1 non-small cell lung cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the PD-1 non-small cell lung cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the PD-1 non-small cell lung cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the PD-1 non-small cell lung cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current PD-1 non-small cell lung cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the PD-1 non-small cell lung cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the PD-1 non-small cell lung cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the PD-1 non-small cell lung cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with PD-1 non-small cell lung cancer across the seven major markets?
What is the size of the PD-1 non-small cell lung cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of PD-1 non-small cell lung cancer?
What will be the growth rate of patients across the seven major markets?
PD-1 Non-Small Cell Lung Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for PD-1 non-small cell lung cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the PD-1 non-small cell lung cancer market?
What are the key regulatory events related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by status related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by phase related to the PD-1 non-small cell lung cancer market?
What is the structure of clinical trial landscape by route of administration related to the PD-1 non-small cell lung cancer market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PD-1 NON-SMALL CELL LUNG CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PD-1 NON-SMALL CELL LUNG CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PD-1 NON-SMALL CELL LUNG CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PD-1 NON-SMALL CELL LUNG CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PD-1 NON-SMALL CELL LUNG CANCER - UNMET NEEDS
10 PD-1 NON-SMALL CELL LUNG CANCER - KEY ENDPOINTS OF TREATMENT
11 PD-1 NON-SMALL CELL LUNG CANCER - MARKETED PRODUCTS
11.1 List of PD-1 Non-Small Cell Lung Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda (Pembrolizumab) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PD-1 NON-SMALL CELL LUNG CANCER - PIPELINE DRUGS
12.1 List of PD-1 Non-Small Cell Lung Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Retifanlimab - Incyte Corporation/Macrogenics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD 2936 - Astrazeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HLX 10 - Shanghai Henlius Biotech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 RO 7247669 - Hoffmann-La Roche
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PD-1 NON-SMALL CELL LUNG CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PD-1 NON-SMALL CELL LUNG CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PD-1 NON-SMALL CELL LUNG CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
16 PD-1 NON-SMALL CELL LUNG CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PD-1 NON-SMALL CELL LUNG CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PD-1 NON-SMALL CELL LUNG CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PD-1 NON-SMALL CELL LUNG CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PD-1 NON-SMALL CELL LUNG CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PD-1 NON-SMALL CELL LUNG CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PD-1 NON-SMALL CELL LUNG CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PD-1 NON-SMALL CELL LUNG CANCER - UNMET NEEDS
10 PD-1 NON-SMALL CELL LUNG CANCER - KEY ENDPOINTS OF TREATMENT
11 PD-1 NON-SMALL CELL LUNG CANCER - MARKETED PRODUCTS
11.1 List of PD-1 Non-Small Cell Lung Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda (Pembrolizumab) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 PD-1 NON-SMALL CELL LUNG CANCER - PIPELINE DRUGS
12.1 List of PD-1 Non-Small Cell Lung Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 Retifanlimab - Incyte Corporation/Macrogenics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD 2936 - Astrazeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 HLX 10 - Shanghai Henlius Biotech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 RO 7247669 - Hoffmann-La Roche
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PD-1 NON-SMALL CELL LUNG CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PD-1 NON-SMALL CELL LUNG CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PD-1 NON-SMALL CELL LUNG CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 PD-1 Non-Small Cell Lung Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 PD-1 Non-Small Cell Lung Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 PD-1 Non-Small Cell Lung Cancer - Access and Reimbursement Overview
16 PD-1 NON-SMALL CELL LUNG CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PD-1 NON-SMALL CELL LUNG CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PD-1 NON-SMALL CELL LUNG CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
